In February, the FDA approved the first cancer therapy based on tumor-infiltrating lymphocytes (TILs). Although most advanced immunotherapies, such as CAR-Ts, have been largely aimed at blood-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback